MICHAEL J. KEATING, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas E4447
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about MICHAEL J. KEATING at radaris.comName
Address
Phone
443 Shady Ln, Little Elm, TX 75068
3532 Creekside Ct, Bedford, TX 76021
3916 Windhaven Rd, Fort Worth, TX 76133
Organization information
See more information about MICHAEL J. KEATING at bizstanding.comUniversity TX MD Anderson Cancer Center - Michael J Keating MD
1515 Holcombe Blvd UNIT 428, Houston, TX 77030
Categories:
Oncology Physicians & Surgeons
Phone:
(713) 745-2376 (Phone)
Professional information
See more information about MICHAEL J. KEATING at trustoria.com
Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
US Patent:
8097468, Jan 17, 2012
Filed:
Oct 21, 2009
Appl. No.:
12/582998
Inventors:
Maher Albitar - Coto de Caza CA, US
Elihu H. Estey - Houston TX, US
Hagop M. Kantarjian - Bellaire TX, US
Francis J. Giles - Bellaire TX, US
Michael J. Keating - Houston TX, US
Elihu H. Estey - Houston TX, US
Hagop M. Kantarjian - Bellaire TX, US
Francis J. Giles - Bellaire TX, US
Michael J. Keating - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 24/00, G01N 1/00, G01N 1/10, G01N 33/00, G01N 33/48, A61K 49/00, A61K 31/00, A01N 61/00
US Classification:
436173, 436 63, 436 64, 436 86, 436174, 436179, 424 91, 424 92, 514 1
Abstract:
The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
US Patent:
7622306, Nov 24, 2009
Filed:
Apr 20, 2005
Appl. No.:
11/110374
Inventors:
Maher Albitar - Coto de Caza CA, US
Elihu H. Estey - Houston TX, US
Hagop M. Kantarjian - Bellaire TX, US
Francis J. Giles - Bellaire TX, US
Michael J. Keating - Houston TX, US
Elihu H. Estey - Houston TX, US
Hagop M. Kantarjian - Bellaire TX, US
Francis J. Giles - Bellaire TX, US
Michael J. Keating - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 24/00, G01N 1/00, G01N 1/10, G01N 33/48, G01N 33/00, A61K 49/00, A01N 61/00, A61K 31/00
US Classification:
436173, 473174, 473179, 473 63, 473 64, 473 86, 424 91, 424 92, 514 1
Abstract:
The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
Use Of Orsaponin [3Beta, 16Beta, 17 Alpha-Trihydroxycholost-5-En-22-One 16-0-(2-0-4-Methoxybenzoyl-Beta-D-Xylopyranosyl)-(1->3)-(2-0-Acetyl-Alpha-L-Arabinopyranoside)] Or Osw-1 And Its Derivatives For Cancer Therapeutics
Use Of Orsaponin [3Beta, 16Beta, 17 Alpha-Trihydroxycholost-5-En-22-One 16-0-(2-0-4-Methoxybenzoyl-Beta-D-Xylopyranosyl)-(1->3)-(2-0-Acetyl-Alpha-L-Arabinopyranoside)] Or Osw-1 And Its Derivatives For Cancer Therapeutics
US Patent:
2005000, Jan 6, 2005
Filed:
Apr 7, 2004
Appl. No.:
10/819479
Inventors:
Peng Huang - Bellaire TX, US
Michael Keating - Houston TX, US
Zhendong Jin - Coralville IA, US
Michael Keating - Houston TX, US
Zhendong Jin - Coralville IA, US
International Classification:
A61K031/704, A61K031/56
US Classification:
514026000, 514169000
Abstract:
The present invention concerns methods for treating pancreatic cancers, leukemias, colon cancers, malignant gliomas and other brain tumors, and ovarian cancers which comprise providing to an individual compositions comprising an orsaponin such as OSW-1 or its derivatives such as 17-deoxyorsaponin. Various therapeutically useful derivatives of orsaponins are also described.
Systems And Methods For Rf-Induced Hyperthermia Using Biological Cells And Nanoparticles As Rf Enhancer Carriers
Systems And Methods For Rf-Induced Hyperthermia Using Biological Cells And Nanoparticles As Rf Enhancer Carriers
US Patent:
2005025, Nov 10, 2005
Filed:
Feb 3, 2005
Appl. No.:
11/050481
Inventors:
John Kanzius - Erie PA, US
William Steinbrink - Erie PA, US
Robert McDonald - Sanibel FL, US
Michael Keating - Houston TX, US
William Steinbrink - Erie PA, US
Robert McDonald - Sanibel FL, US
Michael Keating - Houston TX, US
International Classification:
A61F002/00
US Classification:
607101000
Abstract:
A method of inducing hyperthermia in at least a portion of a target area—e.g., a tumor or a portion of a tumor or targeted cancerous cells—is provided. Targeted RF absorption enhancers, e.g., tumor infiltrating lymphocytes (TILs) containing RF absorbing particles, are introduced into a patient. These targeted RF absorption enhancers will target certain cells in the target areas and enhance the effect of a hyperthermia generating RF signal directed toward the target area. The targeted RF absorption enhancers may, in a manner of speaking, add one or more RF absorption frequencies to cells in the target area, which will permit a hyperthermia generating RF signal at that frequency or frequencies to heat the targeted cells.
Propyl 3-Bromo-2-Oxopropionate And Derivatives As Novel Anticancer Agents
Propyl 3-Bromo-2-Oxopropionate And Derivatives As Novel Anticancer Agents
US Patent:
2006005, Mar 16, 2006
Filed:
Jul 28, 2005
Appl. No.:
11/192281
Inventors:
Peng Huang - Bellaire TX, US
Michael Keating - Houston TX, US
Ruihau Xu - Guangzhou, CN
Michael Keating - Houston TX, US
Ruihau Xu - Guangzhou, CN
International Classification:
A61K 31/22, A61K 31/19
US Classification:
514546000, 514557000
Abstract:
The present invention is directed to compositions that inhibit glycolysis, perferentially in cancer. Specifically, the anticancer compositions comprise 3-halo-2-oxopropionate and its derivatives, such as ester derivatives. However, in specific embodiments, the anticancer composition is sodium 3-halo-2-oxopropionate, such as sodium 3-bromo-2-oxopropionate and a stabilizing agent, such as carbonic acid. In particular embodiments, the compositions of the present invention further comprise a metabolic intermediate for normal cells to utilize in a pathway for an alternate energy source, thereby providing protection to normal cells. In other embodiments, the 3-halo-2-oxopropionate or its ester derivative is used in combination with an additional cancer therapy, such as radiation and/or a drug.
Methods And Compositions To Eliminate Chronic Lymphocytic Leukemia And Other Hematologic Malignant Cells In Stromal Microenvironment For Cancer Therapy
Methods And Compositions To Eliminate Chronic Lymphocytic Leukemia And Other Hematologic Malignant Cells In Stromal Microenvironment For Cancer Therapy
US Patent:
2014003, Jan 30, 2014
Filed:
Nov 22, 2011
Appl. No.:
13/989016
Inventors:
Peng Huang - Bellaire TX, US
Wan Zhang - Houston TX, US
Michael J. Keating - Houston TX, US
Wan Zhang - Houston TX, US
Michael J. Keating - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 31/195, A61K 33/20, A61K 45/06, A61K 31/095
US Classification:
4241331, 514561, 424 937, 514110, 514 48, 514492, 514394, 4241421, 514323
Abstract:
The present invention regards compositions and methods for treating chronic lymphocytic leukemia in the in vivo tissue environment using selenium-containing compositions. In particular aspects, a selenium-comprising compound is administered to an individual wherein the CLL cells are in a stromal cell environment, wherein stromal factors modulate the selenium comprising compound to enhance its activity.
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
US Patent:
7943332, May 17, 2011
Filed:
Apr 16, 2010
Appl. No.:
12/761903
Inventors:
Maher Albitar - Sugarland TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Assignee:
Board of Regents, the University of Texas System - Austin TX
International Classification:
G01N 31/00, G01N 33/53
US Classification:
435 721, 435 71, 436 1, 436501, 436518, 424 91, 424520, 422 1, 422 50, 530300, 530350
Abstract:
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
US Patent:
2014001, Jan 9, 2014
Filed:
Jul 3, 2013
Appl. No.:
13/934940
Inventors:
Michael J. KEATING - Houston TX, US
Taghi MANSHOURI - Houston TX, US
Taghi MANSHOURI - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/68
US Classification:
435 723, 435 792, 435 79
Abstract:
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
US Patent:
8114618, Feb 14, 2012
Filed:
Apr 5, 2011
Appl. No.:
13/080180
Inventors:
Maher Albitar - Sugarland TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Assignee:
Board of Regents of the University of Texas System - Austin TX
International Classification:
G01N 31/00
US Classification:
435 721, 435 4, 435 71, 4352879, 436501, 436518, 436525, 436529, 436535, 436809, 427287, 427337, 427338, 530300, 530350
Abstract:
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
Measuring Circulating Therapeutic Antibody, Antigen And Antigen/Antibody Complexes Using Elisa Assays
US Patent:
8232068, Jul 31, 2012
Filed:
Jan 12, 2012
Appl. No.:
13/349170
Inventors:
Maher Albitar - Sugarland TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Michael J. Keating - Houston TX, US
Taghi Manshouri - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 31/00, G01N 33/53
US Classification:
435 721, 435 4, 435 71, 4352879, 436501, 436518, 436525, 436529, 436535, 436809, 427287, 427337, 427338, 530300, 530350
Abstract:
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.